keyword
breast cancer
her2
her2+
her2-positive
her2-negative
triple negative
tnbc
hr+
hr-
er+
er-
pr+
pr-
metastatic breast cancer
early breast cancer
stage 4 breast cancer
luminal
basal-like
enhertu
kadcyla
herceptin
perjeta
phesgo
verzenio
ibrance
kisqali
trodelvy
lynparza
keytruda
opdivo
tecentriq
imfinzi
destiny-breast
monarche
natalee
asco
sabcs
fda approval
clinical trial
phase 3
phase 2
antibody-drug conjugate
adc
cdk4/6 inhibitor
parp inhibitor
immune checkpoint
neoadjuvant
adjuvant
overall survival
progression-free survival
pathologic complete response
pcr
brca1
brca2
brca mutation
pi3k
akt
mtor
alpelisib
capivasertib
sacituzumab
trastuzumab deruxtecan
abemaciclib
palbociclib
ribociclib
olaparib
talazoparib
pembrolizumab
nivolumab
atezolizumab
durvalumab
breast cancer screening
mammography
genetic testing
precision medicine
targeted therapy
immunotherapy
chemotherapy
radiation therapy
surgical oncology
oncotype dx
mammaprint